Jazz Pharmaceuticals plc Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: Other NEO average total compensation $7.13M.
- 2024-12-31: PEO Bruce C. Cozadd; PEO total compensation $15.53M; PEO compensation actually paid $17.26M; Other NEO average total compensation $4.70M.
- 2023-12-31: PEO Bruce C. Cozadd; PEO total compensation $15.34M; PEO compensation actually paid -$2.50M; Other NEO average total compensation $4.23M.
- 2022-12-31: PEO Bruce C. Cozadd; PEO total compensation $17.33M; PEO compensation actually paid $26.32M; Other NEO average total compensation $5.04M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $7.13M | $10.75M | $103.00 | $124.75 | -$356.15M | total revenues $4.27B | 2026-06-08 | |||
| 2024-12-31 | Bruce C. Cozadd | $15.53M | $17.26M | $4.70M | $5.20M | $74.61 | $93.49 | $560.12M | $4.07B | 2026-06-08 |
| 2023-12-31 | Bruce C. Cozadd | $15.34M | -$2.50M | $4.23M | $208.19K | $74.52 | $94.03 | $414.83M | $3.83B | 2026-06-08 |
| 2022-12-31 | Bruce C. Cozadd | $17.33M | $26.32M | $5.04M | $7.25M | $96.52 | $89.90 | -$224.06M | $3.66B | 2026-06-08 |
| 2021-12-31 | Bruce C. Cozadd | $15.68M | $4.92M | $4.54M | $2.66M | $77.19 | $100.02 | -$329.67M | $3.09B | 2026-06-08 |
| 2024-12-31 | Bruce C. Cozadd | $15.53M | $17.26M | $4.70M | $5.20M | $82.50 | $118.20 | $560.12M | total revenues $4.07B | 2025-06-06 |
| 2023-12-31 | Bruce C. Cozadd | $15.34M | -$2.50M | $4.23M | $208.19K | $82.40 | $118.87 | $414.83M | $3.83B | 2025-06-06 |
| 2022-12-31 | Bruce C. Cozadd | $17.33M | $26.32M | $5.04M | $7.25M | $106.72 | $113.65 | -$224.06M | $3.66B | 2025-06-06 |
| 2021-12-31 | Bruce C. Cozadd | $15.68M | $4.92M | $4.54M | $2.66M | $85.34 | $126.45 | -$329.67M | $3.09B | 2025-06-06 |
| 2020-12-31 | Bruce C. Cozadd | $12.57M | $19.60M | $4.09M | $6.15M | $110.56 | $126.42 | $238.62M | $2.36B | 2025-06-06 |
| 2023-12-31 | Bruce C. Cozadd | $15.34M | -$2.50M | $4.23M | $208.19K | $82.40 | $118.87 | $414.83M | total revenues $3.83B | 2024-06-14 |
| 2022-12-31 | Bruce C. Cozadd | $17.33M | $26.32M | $5.04M | $7.25M | $106.72 | $113.65 | -$224.06M | $3.66B | 2024-06-14 |
| 2021-12-31 | Bruce C. Cozadd | $15.68M | $4.92M | $4.54M | $2.66M | $85.34 | $126.45 | -$329.67M | $3.09B | 2024-06-14 |
| 2020-12-31 | Bruce C. Cozadd | $12.57M | $19.60M | $4.09M | $6.15M | $110.56 | $126.42 | $238.62M | $2.36B | 2024-06-14 |
| 2022-12-31 | Bruce C. Cozadd | $17.33M | $26.32M | $5.04M | $7.25M | $107.00 | $114.00 | -$224.06M | total revenues $3.66B | 2023-06-16 |
| 2021-12-31 | $15.68M | $4.92M | $4.54M | $2.66M | $85.00 | $126.00 | -$329.67M | $3.09B | 2023-06-16 | |
| 2020-12-31 | $12.57M | $19.60M | $4.09M | $6.15M | $111.00 | $126.00 | $238.62M | $2.36B | 2023-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |